MedTrace Logo

Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger

NCT04409483 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-02-10

No results posted yet for this study

Summary

The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.

Conditions

Interventions

DRUG

Lopinavir-Ritonavir Drug Combination

400mg/100mg taken orally twice daily for 14 days.

COMBINATION_PRODUCT

Standard Care

Paracetamol as needed for the symptomatic treatment of fever and vitamin C 1000 mg daily

Sponsors & Collaborators

  • Université Abdou Moumouni

    collaborator UNKNOWN

  • Centre de Recherche Médicale et Sanitaire

    collaborator OTHER

  • Ministry of Public Health, Republic of Niger

    collaborator UNKNOWN

  • Epicentre

    lead OTHER

Principal Investigators

  • Rebecca F Grais · Epicentre

  • Eric Adehossi · Hôpital Général de Référence de Niamey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2020-12-31
Completion
2020-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04409483 on ClinicalTrials.gov